Oxford, United Kingdom — HydRegen, a University of Oxford spinout that makes enzyme-based catalysts for industrial chemical manufacturing, has closed $8 million (£6 million) in the first close of its Series A financing. The round was led by Genoa Ventures, with participation from Clean Growth Fund and First Imagine! Ventures, alongside existing backers Oxford Technology Management, Headington Holdings, Oxonian, Foxglove Capital and Rapid Innovation Group.
The funding will let HydRegen expand work with existing customers in pharmaceuticals and specialty chemicals and push into chemicals, agrochemicals, materials and bulk chemicals — a notable step up from its earlier fine-chemicals focus into higher-volume markets.
What HydRegen Actually Does
Hydrogenation — adding hydrogen to molecules — is one of the most common chemical reactions in the world. It shows up in an estimated 14 to 20 percent of all processes in the trillion-dollar industrial chemicals market, and it is how manufacturers make everything from drug ingredients to crop-protection chemicals to specialty materials.
For decades, hydrogenation has been done with precious-metal catalysts, typically platinum-group metals. These work, but they are expensive, often toxic, sometimes flammable, and they can be hard to remove from final products — a particular problem in pharmaceutical manufacturing where metal contamination is tightly regulated. They also rely on supply chains tied to a small number of mining regions, which creates price volatility.
HydRegen's answer is to make biology perform like chemistry. The company produces a hydrogenase enzyme through fermentation, then formulates it into a suite of proprietary catalyst platforms — including its Bio2Amine technology — that let the same enzyme drive hundreds of different hydrogenation reactions. Because the enzymes run at milder temperatures and pressures than metal-catalyzed processes, manufacturers can cut energy use as well as materials costs. HydRegen claims its platform can make chemical manufacturing up to 40 percent more cost-effective while lowering carbon emissions.
The technology's roots trace back to research by Professor Kylie Vincent and Dr. Holly Reeve at the University of Oxford. Early work immobilized hydrogenase enzymes from the bacterium Cupriavidus necator onto carbon beads, using hydrogen gas to recycle NADH, an expensive cofactor that had long blocked industrial adoption of biocatalysis. The company spun out of Oxford in 2021, led by CEO Dr. Holly Reeve and Chief Scientific Officer Dr. Sarah Cleary, and previously raised a £2.6 million round led by Clean Growth Fund to commercialize the platform.
The Drop-In Advantage
The single most important design decision in HydRegen's story is its "drop-in" approach. Rather than asking manufacturers to rebuild plants around new biology, the company engineered its catalysts to work in the equipment manufacturers already own. As CEO Holly Reeve put it, manufacturers can "change the catalyst without changing the factory."
This matters because green-chemistry startups have repeatedly failed on the adoption curve: the science worked in the lab, but scaling required customers to retool, requalify processes, or take on construction risk. HydRegen's pitch sidesteps all of that. An enzyme catalyst that turns over millions of times in existing reactors offers cost savings and sustainability gains without capital expenditure on the customer's side — which is why the company has traction in pharmaceuticals and specialty chemicals, industries where requalification is slow but payoff is large.
The Competitive Landscape
HydRegen sits at the intersection of industrial biotechnology and sustainable chemistry, a field that has attracted significant attention as regulations tighten. Competitors include engineered-enzyme companies like Codexis and Ginkgo Bioworks' enzyme-engineering programs, as well as process-chemistry firms developing alternative catalyst technologies. What distinguishes HydRegen is its focus on hydrogenation specifically — one of the biggest addressable steps in chemical manufacturing — and its decision to harness one enzyme across many reactions rather than engineering a new biocatalyst for each process, which keeps unit economics favorable for cost-sensitive bulk markets.
What the Raise Means
For founders in deep tech, HydRegen's trajectory is instructive. The company spent five years moving from Oxford spinout to Series A with demonstrated customer demand, choosing capital efficiency over flashy scale-ups. Genoa Ventures' Jenny Rooke framed the investment exactly that way, citing "great science, solid economics, a path to scale, capital efficiency, and demonstrated customer demand."
For investors, the signal is that climate-tech capital is flowing toward technologies that work within existing industrial infrastructure rather than demanding it be replaced. Clean Growth Fund's follow-on participation — having led the company's earlier round — suggests confidence that biocatalysis is moving from pilot projects into genuine commercial deployment. With its first Series A close complete, HydRegen is positioned to test whether enzyme catalysts can scale from fine chemicals into the high-volume bulk markets where the real decarbonization gains lie.
Angeled.com connects founders with investors.
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



